Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Regeneron Pharmaceuticals's accounts receivables for the quarter that ended in Dec. 2023 was $5,667 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Regeneron Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 150.58.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Regeneron Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $84.80.
Regeneron Pharmaceuticals Accounts Receivable Historical Data
The historical data trend for Regeneron Pharmaceuticals's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Regeneron Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Regeneron Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:
Regeneron Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Regeneron Pharmaceuticals Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your 